The fallout from the CHAMPION trials of the new IV antiplatelet agent cangrelor in PCI was one of the main talking points at the American Heart Association 2009 Scientific Sessions. The first IV P2Y12 antagonist inhibited platelet activity more effectively than clopidogrel, but this did not translate into a reduction of the primary end point in the two trials.

Join heartwire journalist Sue Hughes as she talks to trial investigators Drs Bob Harrington and Gregg Stone and clinical-trials guru Dr Sanjay Kaul about why the CHAMPION results didn't live up to expectations and why we should give cangrelor a second chance.